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Abstract Craniopharyngiomas are locally aggressive
tumors which typically are focused in the sellar and
suprasellar region near a number of critical neural and
vascular structures mediating endocrinologic, behavioral,
and visual functions. The present study aims to summarize
and compare the published literature regarding morbidity
resulting from treatment of craniopharyngioma. We per-
formed a comprehensive search of the published English
language literature to identify studies publishing outcome
data of patients undergoing surgery for craniopharyngioma.
Comparisons of the rates of endocrine, vascular, neuro-
logical, and visual complications were performed using
Pearson’s chi-squared test, and covariates of interest were
fitted into a multivariate logistic regression model. In our
data set, 540 patients underwent surgical resection of their
tumor. 138 patients received biopsy alone followed by
some form of radiotherapy. Mean overall follow-up for all
patients in these studies was 54 ± 1.8 months. The overall
rate of new endocrinopathy for all patients undergoing
surgical resection of their mass was 37% (95% CI = 33–
41). Patients receiving GTR had over 2.5 times the rate of
developing at least one endocrinopathy compared to
patients receiving STR alone or STR ? XRT (52 vs. 19 vs.
20%, v2 P \ 0.00001). On multivariate analysis, GTR
conferred a significant increase in the risk of endocrinop-
athy compared to STR ? XRT (OR = 3.45, 95% CI =
2.05–5.81, P \ 0.00001), after controlling for study size
and the presence of significant hypothalamic involvement.
There was a statistical trend towards worse visual out-
comes in patients receiving XRT after STR compared to
GTR or STR alone (GTR = 3.5% vs. STR 2.1% vs.
STR ? XRT 6.4%, P = 0.11). Given the difficulty in
obtaining class 1 data regarding the treatment of this tumor,
this study can serve as an estimate of expected outcomes
for these patients, and guide decision making until these
data are available.
Keywords Craniopharyngioma  Surgery  Morbidity 
Radiotherapy  Radiosurgery
Introduction
Craniopharyngiomas are locally aggressive tumors which
typically are focused in the sellar and suprasellar region
near a number of critical neural and vascular structures
mediating endocrinologic, behavioral, and visual functions.
Multimodality therapy for these tumors can be challenging,
given the significant potential for harm with any inter-
vention involving the structures in this region, as well as
the young age of many of the patients with these lesions.
For many years, gross total resection (GTR) was felt to
be the treatment of choice, given the better rates of tumor
control compared to subtotal resection (STR) alone, and the
avoidance of radiotherapy in young patients. Experience
with aggressive surgical resection has led some to conclude
that a general goal of GTR in all cases might lead to
unacceptable rates of endocrinologic and behavioral mor-
bidity, and that GTR could be replaced with subtotal
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debulking followed by stereotactic conformal radiotherapy
[1–4]. This potential benefit must be tempered against the
risk of radiation induced injury to nearby radiosensitive
normal structures, notably the optic chiasm [5, 6]. The
present study aims to summarize and compare the pub-
lished literature regarding morbidity resulting from treat-
ment of craniopharyngioma.
Materials and methods
Article selection
Articles were identified via a PubMed search using the key
phrases ‘‘craniopharyngioma,’’ alone and in combination
with ‘‘optic,’’ ‘‘morbidity,’’ ‘‘pituitary,’’ ‘‘hypopituita-
rism,’’ ‘‘endocrine,’’ ‘‘complications,’’ ‘‘visual,’’ and
‘‘vision.’’ Inclusion criteria were: (1) All patients had to
have follow-up data available. (2) Articles had to have
enough information for each patient to be disaggregated.
The rationale for the exclusion of aggregated data sets is
described below. Exclusion criteria were: (1) Articles that
combined patient outcomes of craniopharyngioma with
other childhood tumors were excluded, unless there was a
clear distinction between the two separate groups of
patients. (2) Rathke’s Pouch tumors were excluded from
this study. After reviewing these articles, a thorough
review of all referenced sources was also performed.
All references that contained disaggregated data
specifically addressing complication rates with adequate
follow up in patients who had undergone surgical resection
with or without fXRT or stereotactic radiosurgery (SRS) as
adjuvant or monotherapy were included in our analysis. In
addition, we included patients undergoing surgery via the
extended transsphenoidal route in the surgery cohort,
where appropriate.
Data extraction
Our searches yielded a total of 274 studies [3, 7–279]
(Table 1) reporting data for 8058 non-duplicated cranio-
phayngioma patients. After analyzing the complication
rates in aggregated cohorts, we concluded that complica-
tion rates were likely underreported in aggregated data sets
(for example, the reported rate of endocrinopathy with
GTR was 2.1% in the aggregated datasets, compared with a
more realistic 52% in series which presented individual
patients separately). Thus, we chose to analyze only these
disaggregated datasets.
Disaggregated data useable for analysis were presented
for 800 individual patients. Data were stratified into five
groups based on treatment paradigm: STR alone, GTR
alone, STR plus adjuvant post-operative radiotherapy
Table 1 Pubmed ID’s of identified studies
102623 3984798 8607079 11322455 15141142 16700314
290201 4084876 8748817 11345343 15185112 16700318
290203 4308176 8869189 11441284 15206435 16798405
290204 4542715 8869774 11465396 15272926 16825115
290207 5059968 8883637 11515727 15290187 16850111
408309 5573248 9007857 11585327 15322844 16888556
430156 5648949 9068702 11685525 15335421 17015135
615967 5821004 9112447 11740179 15367800 17041520
622676 5842310 9224913 11769865 15558704 17042979
928713 6156805 9298276 11810394 15570985 17046151
975700 6168950 9361074 11841735 15670196 17161483
1011020 6293388 9361075 11862438 15681858 17185886
1110394 6381061 9364961 11938361 15759158 17233305
1174243 6470759 9440495 11942362 15800425 17330531
1403127 6511526 9482551 11949829 15807869 17337922
1414528 6657077 9728244 11961313 15851090 17407137
1527612 6673882 9782245 11981627 15871507 17415187
1669245 6833018 9806520 11990811 15895298 17469176
1727168 6853252 9814465 12060820 15928963 17533510
1772600 6886754 9840379 12062594 15931512 17566208
1803868 7099406 9950494 12099569 15957193 17592268
1955511 7104980 9950495 12116534 15959732 17627142
2002381 7105886 10066013 12134929 15959733 17762741
2013769 7121821 10070421 12197795 15959734 18311527
2080379 7264728 10086237 12243827 15959735
2095298 7413035 10232528 12376777 15965667
2116387 7431164 10424206 12382167 15971075
2204689 7438834 10433322 12419438 15989759
2311109 7530989 10445444 12420123 15995885
2352012 7530989 10461071 12447234 16001286
2398383 7568823 10616560 12456941 16028088
2441286 7596502 10616561 12495299 16034620
2494851 7616262 10659012 12507105 16044343
2501242 7619722 10681689 12507107 16055476
2672706 7673031 10690718 12555247 16124175
2689398 7818929 10703499 12677102 16133275
2894566 7841079 10726829 12786772 16133276
2912938 7841080 10760417 12820755 16133277
3336845 7841081 10867561 12823875 16175850
3396018 7841082 10883334 12825216 16216361
3396019 7841084 10892270 12845200 16320025
3442400 7841085 10975938 12922045 16327556
3489356 7885544 11013625 12925239 16383245
3628817 7942198 11014425 14519213 16500745
3712025 8021691 11118572 14558670 16580494
3738985 8027806 11124639 14961770 16630407
3794057 8272006 11131489 14967425 16700308
3799245 8327728 11143262 15035280 16700310
3968554 8422329 11155065 15040718 16700311
3968556 8438080 11234912 15046646 16700313
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(STR ? XRT), biopsy followed by fractionated radiother-
apy (fXRT), or biopsy followed by radiosurgery (SRS)
alone. We did not directly compare the radiation only
groups (SRS and fXRT) to the surgically treated patients.
Endocrinopathy was defined as the development of any
new monohormonal or polyhormonal anterior hypopitu-
itarism, or diabetes insipidus. Vascular injury referred to
any gross injury to the circle of Willis or perforating vessel,
as well as any reported post-treatment cerebral infarction.
Neurologic injury referred to the development of a post-
treatment non-endocrine, non-visual neurologic deficit.
Visual deterioration was defined as permanent loss or
decrease in visual acuity, or a new visual field cut in either
eye. Studies which did not present patient data in a way
that these variables could reliably be determined were
excluded from further analysis.
Statistical analysis
Pearson’s v2 test was used to analyze for differences in
categorical factors. Fisher’s exact test was used if there
were less than five values per cell. Analysis of variance
(ANOVA) was used to evaluate for statistical differences in
pre-operative continuous factors, including age and tumor
size. Post-hoc between group analyses were performed
when the ANOVA demonstrated P \ 0.05 using Tukey’s
test. All analyses were carried out using SPSS version 16.0
(SPPS, Inc.).
Logistic regression analysis
Univariate analysis was used to identify covariates which
might affect the rate of neurologic, endrocrinologic, vas-
cular, or visual complications in these patients. Binary and
categorical variables were compared using Pearson’s v2
test, or the v2 test for trend, respectively. Cut-offs for
variables were determined empirically by first analyzing
the data in smaller categories, and then aggregating groups
which seemed statistically homogeneous. Variables which
impacted rates of complication with a P = 0.2 or less on
univariate analysis were included in stepwise binary
logistic regression modeling [280]. All odds ratios on
multivariate analysis, reflect the risk of having nonservi-
cable hearing a neurologic or endocrine complication
compared to the reference group. Reference groups inclu-
ded the STR ? XRT cohort for the extent of resection
analysis and the large sample size studies for the surgeon
experience analysis. The goodness of fit of the regression
model was confirmed by demonstrating a non-significant
P-value on the Hosmer-Lemeshow test [280, 281].
We tested interaction terms between each of the three
variables to significantly impact hearing on univariate
analysis. The statistical significance of the interactions was
assessed with the use of backward stepwise regression, in
which statistical significance was estimated by means of the
likelihood-ratio test to assess the effect of removing inter-
action terms for all strata of the given variable [280]. After
finding that none of the interaction terms would significantly
(unadjusted P [ 0.2 for all terms) alter the log likelihood of
the regression model if removed, we calculated the adjusted
odds ratios without adjusting for interactions.
Of note, while tumor size is a variable of interest, it is
inconsistently presented in most studies, and we were only
able to collect data on tumor size for 87 patients. Because
these data were not enough to include in the multivariate
regression modeling, we present only univariate data
regarding the relationship between tumor size and
complications.
Results
Clinical characteristics of included patients
In our data set, 540 patients underwent surgical resection of
their tumor. GTR was achieved in 289 cases, while STR
was achieved in 251 cases. Of patients receiving STR, 110
patients received fXRT, and 141 did not. Surgical patients
in different cohorts did not differ in mean age at the time of
surgery, gender distribution, or pre-operative tumor size.
138 patients received biopsy alone followed by some
form of radiotherapy. 72/138 of these patients received
fXRT, and 66/138 patients received SRS. Age and gender
distribution did not differ between patients receiving fXRT
and SRS.
The remaining patients did not have adequate data to
facilitate our analysis and were excluded. Mean overall
follow-up for all patients in these studies was 54 ±
1.8 months.
The mean number of patients per study was 5.8 patients,
(range 1–45 patients per study). 34% of the patients in the
study came from series of 10 or less patients, 22% came from
series of 10–20 patients, and 43% came from series larger
than 20 patients. The modest sample sizes in many of the
included studies is an inevitable consequence of the decision
to use only disaggregated data, as larger studies generally
provide summary statistics instead of individual patient
data, and as discussed below, frequently do not report rates
of morbidity in a way which can be realistically analyzed.
The rates of neurologic injury after treatment
for craniopharyngioma
New neurologic deficits were reported in 5.1% of patients
undergoing surgery (95% CI = 3.3–7.1), and in 2.2% of
patients undergoing fXRT or SRS alone (95% CI = 0–4.6)
J Neurooncol (2011) 101:463–476 465
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(Table 2). There was no statistically significant difference
in the rates of neurologic deficits between patients receiv-
ing GTR alone, STR alone, or STR ? XRT (6.9 vs. 4.2 vs.
1.8%, P = NS) in the univariate analysis, or between
patients receiving fXRT and those receiving SRS (1.4 vs.
3.0%, P = NS) (Fig. 2).
Interestingly, on multivariate analysis, GTR conferred a
significant increase in the risk of neurologic deficits com-
pared to STR ? XRT (OR = 5.05, 95% CI = 1.15–22.21,
P = 0.03) (Table 5), after controlling for study size.
Gross total resection markedly increases the rate
of endocrinopathy
The overall rate of new endocrinopathy for all patients
undergoing surgical resection of their mass was 37% (95%
CI = 33–41) (Table 2). Table 3 summarizes the rates of
individual endocrinopathies. Significant monoendocrinop-
athies of TSH and ACTH were reported commonly, as was
diabetes insipidus (DI). Anterior panhypopituitarism was
reported in as many as 11.8% in patients undergoing GTR.
Patients receiving GTR had over 2.5 times the rate of
developing at least one endocrinopathy compared to
patients receiving STR alone or STR ? XRT (52 vs. 19 vs.
20%, v2 P \ 0.00001) (Fig. 1). The rates of endocrinopa-
thy for patients receiving fXRT alone were not reported,
and thus these data were not analyzed.
On multivariate analysis, GTR conferred a significant
increase in the risk of endocrinopathy compared to
STR ? XRT (OR = 3.45, 95% CI = 2.05–5.81,
P \ 0.00001) (Table 5), after controlling for study size and
the presence of significant hypothalamic involvement.
The rates of vascular injury after surgery
for craniopharyngioma
Vascular injury was an uncommon complication of crani-
opharyngioma surgery, occurring in just two cases (95%
CI = 0–0.9) (Table 2), both resulting in ischemic cerebral
infarction. No vascular complications were reported in any
patients undergoing radiation treatment alone.
The rates of visual decline after treatment
for craniopharyngioma
Visual decline was reported in 3.7% of patients undergoing
surgery (95% CI = 2.1–5.3), and 8.6% of patients under-
going fXRT or SRS alone (95% CI = 3.9–13.4) (Table 2).
Table 2 Summary of overall rates of morbidity
95% CI
Endocrinopathy
Surgery 33–41
fXRT/SRS 8.8–28
Vascular injury
Surgery 0–0.9
fXRT/SRS 0
Neurologic deficit
Surgery 3.3–7.1
fXRT/SRS 0–4.6
Vision deterioration
Surgery 2.1–5.3
fXRT/SRS 3.9–13.4
Table 3 Summary of various
types of monohormonal and
polyhormonal endocrinopathy
following treatment of
craniopharyngioma
GTR (%) STR (%) STR ? XRT (%) fXRT SRS (%)
Hyperprolactinemia 0.0 0.0 0.9 N/A 0.0
Hypogonadism 3.5 2.1 1.8 N/A 3.0
Hypothyroid 13.8 5.7 1.8 N/A 7.6
GH deficiency 6.2 1.4 1.8 N/A 0.0
ACTH deficiency 14.5 6.4 0.9 N/A 3.0
Anterior panhypopituitarism 11.8 3.5 10.0 N/A 3.0
DI 18.7 6.4 5.5 N/A 0.0
Obesity 2.1 0.7 2.7 N/A 1.5
Any endocrinopathy 51.9 19.9 20.0 N/A 18.2
Fig. 1 Comparison of 95% confidence intervals of rates of endocri-
nopathy for patients treated with different modalities for
craniopharyngioma
466 J Neurooncol (2011) 101:463–476
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There was a statistical trend towards worse visual out-
comes in patients receiving XRT after STR compared to
GTR or STR alone (GTR = 3.5% vs. STR 2.1% vs.
STR ? XRT 6.4%, P = 0.11). Visual outcomes did not
differ between patients receiving fXRT and those receiving
SRS (11.1 vs. 6.1%, P = NS) (Fig. 2).
Univariate risk factors for morbidity
after craniopharyngioma surgery
Table 4 demonstrates univariate comparisons of rates of
morbidities with patients stratified by age, tumor size, and
extent of hypothalamic involvement. Note that in our uni-
variate analysis, Patient age was not a significant univariate
predictor of any form of complication, regardless of where
the cut-off was placed in this analysis (one such analysis is
provided in Table 4). Extensive hypothalamic involvement
did increase the risk of endocrinologic complications,
however this was not an independent predictor of morbidity
when extent of resection was controlled for (Table 5).
As stated in the methods, while tumor size is a variable of
interest, it is inconsistently presented in most studies, and
we were only able to collect data on tumor size for 87
patients. Because these data were not enough to include in
the multivariate regression modeling, we present only uni-
variate data regarding the relationship between tumor size
and complications. Patients undergoing surgery for tumors
with a size greater than or equal to 3 cm experienced a
statistical trend towards a higher rate of neurologic com-
plications compared to patients with smaller tumors (10 vs.
0%, P = 0.06) (Table 4). The rates of endocrinologic,
vascular, and visual complications were similar between
patients with larger and smaller tumors (Fig. 3).
Fig. 2 Comparison of 95% confidence intervals of rates of neuro-
logic injury for patients treated with different modalities for
craniopharyngioma
Table 4 Univariate analyses of the effect of potential confounding
variables on rates of neurologic, endocrinologic, vascular, and visual
morbidity in the published literature
Neurologic Endocrine Vascular Visual
# Patients in study
1–10 9% 2% 1% 6%
11–20 2% 7% 0% 2%
21? 1% 1% 0% 4%
P \ 0.001 P \ 0.01 P = 0.12 P = 0.45
Patient age
0–2 9% 48% 0% 4%
2.1–5 5% 41% 0% 0%
5.1–10 5% 44% 1% 2%
11–20 5% 34% 0% 2%
21–50 5% 37% 1% 4%
51? 2% 31% 0% 3%
P = 0.84 P = 0.41 P = 0.85 P = 0.73
Tumor size
\3 cm 0% 36% 0% 6%
C3 cm 10% 43% 2% 0%
P = 0.06 P = 0.33 P = 0.59 P = 0.16
Hypothalamic involvement
Minor or none 5% 40% 5% 3%
Extensive 5% 33% 5% 5%
P = 0.50 P = 0.09 P = 0.43 P = 0.35
Table 5 Multivariate logistic regression demonstrating the risk of
neurologic and endocrinologic morbidity controlling for extent of
resection, study size, and presence of extensive hypothalamic
involvement
OR 95% CI P-value
- ?
Neurologic
GTR 5.05 1.15 22.21 0.03
STR 2.41 0.45 12.79 0.30
Study size 1–10 2.54 1.02 6.29 0.04
Study size 11–20 0.31 0.06 1.53 0.15
Endocrine
Extensive hypothalamic
involvement
1.28 0.78 2.08 0.33
GTR 3.45 2.05 5.81 \0.00001
STR 1.89 1.05 3.38 0.03
Study size 1–10 1.02 0.66 1.58 0.92
Study size 11–20 0.61 0.35 1.05 0.08
Note that the odds ratio for the GTR and STR groups are expressed
relative to the STR ? XRT group, and that the odds ratios for the
study size groups are expressed relative to studies with the group with
the largest study size
J Neurooncol (2011) 101:463–476 467
123
The effect of surgical experience on rates of morbidity
following treatment for craniopharyngioma
Surgical experience is generally not specifically reported in
craniopharyngioma series in the literature. Using the
sample size in these studies as a surrogate for surgical
experience, we found a significant reduction in rates of
most complications with increasing sample size (Table 4).
More specifically, there was a linear decrease in the rates of
neurologic complications with increasing study sample size
(1–10 patients: 9%, 11–20 patients: 2%, 21? patients: 1%,
P \ 0.0001), and a decrease in rates of endocrinopathy
favoring studies larger than 20 patients (1–10 patients: 2%,
11–20 patients: 7%, 21? patients: 1%, P \ 0.01). Vascular
injuries were also only reported in small series 1–10
patients: 1%, 11–20 patients: 0%, 21? patients: 0%,
P = 0.12), however this did not reach statistical signifi-
cance due to the small number of events. Rates of visual
complications did not differ between groups of different
sample size (1–10 patients: 6%, 11–20 patients: 2%, 21?
patients: 4%, P = 0.45).
On multivariate analysis, studies with small sample
sizes remained an independent predictor of increased rates
of neurologic morbidity compared to those with large
sample size (OR = 2.54, 95% CI = 1.02–6.29, P = 0.04)
(Table 5), after controlling for treatment paradigm
administered. Study sample size was not an independent
predictor of endocrinologic morbidity on multivariate
analysis.
Discussion
Currently, there are few definitive studies regarding man-
agement strategies for patients with craniopharyngiomas.
This study aims to utilize a systematic collection of the
published data on craniopharyngioma, to critically evaluate
the idea that subtotal resection with adjuvant radiotherapy
can serve as a desirable replacement for gross total resec-
tion, with lower post-surgical rates of monohormonal and
panhormonal hypothalamic/pituitary endocrinopathy.
Based on our analyses, endocrinopathy is a common
iatrogenic complication of treatment of craniopharyngio-
mas with either surgical resection or radiosurgery, however
it is not unexpectedly higher with surgery. Gross total
resection markedly increases the rate of hormonal distur-
bances compared to subtotal resection with or without
radiotherapy, with over half of patients experiencing at
least one endocrinopathy, and over 10% of patients being
left with panhypopituitarism. Even after correcting for as
many covariates as the data would allow, GTR still
increased the rate of post-operative endocrinopathy by over
three fold. These data support the concept that attempting
gross total resection in these lesions is a difficult trade of
endocrine function for tumor control, and that subtotal
resection might be better for the patient’s overall quality of
life. Further, previous work focusing on craniopharyngi-
oma suggests that craniopharyngiomas frequently recur
despite GTR, and that subtotal resection followed by
adjuvant radiotherapy provides similar rates of tumor
control to that achieved with gross total resection [282].
Taken together, these data argue that gross total resection
of craniopharyngiomas may not be the best treatment
option for most patients, however further work specifically
focusing on the quality of life concerns of patients under-
going these treatment paradigms is needed to definitively
conclude that STR ? XRT is better for the patients than
GTR.
The remaining argument against adjuvant radiation in
this region is the risk of visual deterioration with admin-
istering radiotherapy or radiosurgery in close proximity to
the optic apparatus. In our study, all irradiated patient
cohorts experienced an increased rate of visual compro-
mise compared to surgery only cohorts. While adjuvant
radiotherapy following subtotal cytoreductive surgery did
not reach statistical significance for worse visual outcomes,
It is possible that a lack of statistical power in our cohort
prevented statistical significance that would have been
demonstrated by a larger study. It is important to note that
this difference might be as large as a 10% in visual decline
over GTR at the extremes of the confidence intervals,
which would be a serious argument in favor of eliminating
the need for XRT with GTR. This idea clearly deserves
additional inquiry, especially for driving subtotal resections
towards a targeted attack aimed at creating distance
between the tumor and the optic apparatus.
Additionally, our analysis demonstrates that experience
with craniopharyngiomas matters, and that experienced
surgeons have lower rates of complications, even after
Fig. 3 Comparison of 95% confidence intervals of rates of visual
compromise for patients treated with different modalities for
craniopharyngioma
468 J Neurooncol (2011) 101:463–476
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correcting for tumor characteristics, and surgical philoso-
phy. More specifically, using study size as a surrogate for
surgical experience, more experienced surgeons have lower
rates of neurologic complications than less experienced
surgeons. We speculate that increased familiarity with the
pathoanatomy of these tumors, combined with decreased
need for brain retraction by experienced surgeons, leads to
decreased rates of injury of surrounding neural structures.
Study limitations
While these findings represent a helpful summary of the
published literature on this topic, an analysis of published
data is limited by the data published by others, and may
reflect source study biases. It is impossible for us to control
for the quality of the data reported in the literature. For
example, the majority of this data set is derived from self-
reported outcomes largely assessed by the treating surgeon
and colleagues. It is impossible for us to assess or control
for the quality of the data reported in the literature, or the
unwillingness to report complications. Such omissions
would inevitably change the rates reported in our study.
Further, subjectively defined variables, such as histologic
diagnosis, extent of resection, and the adequacy of radia-
tion therapy likely vary between studies, and we cannot
independently confirm the validity of these definitions in
other groups’ publications.
Finally, due to the diverse range of data presentation, the
number of variables able to be studied and controlled for is
limited. Variables that might be of interest which are
inconsistently presented across studies cannot be reviewed.
Specifically, we cannot completely control for the effect of
tumor size on rates of complications, because unfortu-
nately, not everyone publishes these data.
Conclusion
In this study, we summarized and compared the rates of
endocrine, neurologic, vascular, and visual complications
reported in craniopharyngioma patients. Given the diffi-
culty in obtaining class 1 data regarding the treatment of
this tumor, this study can serve as an estimate of expected
outcomes for these patients, and guide decision making
until these data become available.
Acknowledgments Dr Parsa is supported, in part, by the Reza and
Georgianna Khatib endowed chair in skull base tumor surgery.
Dr Sughrue is supported by the AANS NREF. Mr Rutkowski is
supported by the Doris Duke foundation. Mr Kane is supported by the
Howard Hughes Medical Foundation and the Ivy Foundation.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Habrand JL, Saran F, Alapetite C, Noel G, El Boustany R, Grill
J (2006) Radiation therapy in the management of craniopha-
ryngioma: current concepts and future developments. J Pediatr
Endocrinol Metab 19 Suppl 1:389–394
2. Merchant TE, Kiehna EN, Kun LE, Mulhern RK, Li C, Xiong X,
Boop FA, Sanford RA (2006) Phase II trial of conformal radi-
ation therapy for pediatric patients with craniopharyngioma and
correlation of surgical factors and radiation dosimetry with
change in cognitive function. J Neurosurg 104:94–102
3. Minniti G, Saran F, Traish D, Soomal R, Sardell S, Gonsalves A,
Ashley S, Warrington J, Burke K, Mosleh-Shirazi A, Brada M
(2007) Fractionated stereotactic conformal radiotherapy fol-
lowing conservative surgery in the control of craniopharyngio-
mas. Radiother Oncol 82:90–95
4. Scarzello G, Buzzaccarini MS, Perilongo G, Viscardi E, Faggin
R, Carollo C, Calderone M, Franchi A, Sotti G (2006) Acute and
late morbidity after limited resection and focal radiation therapy
in craniopharyngiomas. J Pediatr Endocrinol Metab 19 Suppl
1:399–405
5. Raimondi AJ, Rougerie J (1994) A critical review of personal
experiences with craniopharyngioma: clinical history, surgical
technique and operative results. 1983. Pediatr Neurosurg
21:134–150 (discussion 151-134)
6. Rienstein S, Adams EF, Pilzer D, Goldring AA, Goldman B,
Friedman E (2003) Comparative genomic hybridization analysis
of craniopharyngiomas. J Neurosurg 98:162–164
7. Long-term outcomes for surgically resected craniopharyngio-
mas. Neurosurgery 46: 291-302; discussion 302-295, 2000
8. Abe T, Ludecke DK (1999) Transnasal surgery for infradia-
phragmatic craniopharyngiomas in pediatric patients. Neuro-
surgery 44:957–964 (discussion 964-956)
9. Adamson TE, Wiestler OD, Kleihues P, Yasargil MG (1990)
Correlation of clinical and pathological features in surgically
treated craniopharyngiomas. J Neurosurg 73:12–17
10. Adeloye A, Nottidge VA, Udi J (1988) Craniopharyngioma in
Nigerian children. Childs Nerv Syst 4:128–134
11. Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino
M, Cuccurullo L (2006) Morphological and ultrastructural
findings of prognostic impact in craniopharyngiomas. Ultrastruct
Pathol 30:143–150
12. Albright AL, Hadjipanayis CG, Lunsford LD, Kondziolka D,
Pollack IF, Adelson PD (2005) Individualized treatment of
pediatric craniopharyngiomas. Childs Nerv Syst 21:649–654
13. Al-Mefty O, Ayoubi S, Kadri PA (2007) The petrosal approach
for the total removal of giant retrochiasmatic craniopharyngio-
mas in children. J Neurosurg 106:87–92
14. al-Mefty O, Kersh JE, Routh A, Smith RR (1990) The long-term
side effects of radiation therapy for benign brain tumors in
adults. J Neurosurg 73:502–512
15. Amendola BE, Gebarski SS, Bermudez AG (1985) Analysis of
treatment results in craniopharyngioma. J Clin Oncol 3:252–258
16. Amendola BE, Wolf A, Coy SR, Amendola MA (2003) Role of
radiosurgery in craniopharyngiomas: a preliminary report. Med
Pediatr Oncol 41:123–127
J Neurooncol (2011) 101:463–476 469
123
17. Ammirati M, Samii M, Sephernia A (1990) Surgery of large
retrochiasmatic craniopharyngiomas in children. Childs Nerv
Syst 6:13–17
18. Anderson CA, Wilkening GN, Filley CM, Reardon MS,
Kleinschmidt-DeMasters BK (1997) Neurobehavioral outcome
in pediatric craniopharyngioma. Pediatr Neurosurg 26:255–260
19. Apuzzo ML, Chikovani OK, Gott PS, Teng EL, Zee CS,
Giannotta SL, Weiss MH (1982) Transcallosal, interfornicial
approaches for lesions affecting the third ventricle: surgical
considerations and consequences. Neurosurgery 10:547–554
20. Aydin Y, Can SM, Gulkilik A, Turkmenoglu O, Alatli C, Ziyal I
(1999) Rapid enlargement and recurrence of a preexisting in-
trasellar craniopharyngioma during the course of two pregnan-
cies. Case report. J Neurosurg 91:322–324
21. Barajas MA, Ramirez-Guzman G, Rodriguez-Vazquez C,
Toledo-Buenrostro V, Velasquez-Santana H, del Robles RV,
Cuevas-Solorzano A, Rodriguez-Hernandez G (2002) Multi-
modal management of craniopharyngiomas: neuroendoscopy,
microsurgery, and radiosurgery. J Neurosurg 97:607–609
22. Barlas O, Bayindir C, Can M (2000) Interstitial irradiation for
craniopharyngioma. Acta Neurochir (Wien) 142:389–395
23. Bartlett JR (1971) Craniopharyngiomas—a summary of 85
cases. J Neurol Neurosurg Psychiatry 34:37–41
24. Barua KK, Ehara K, Kohmura E, Tamaki N (2003) Treatment of
recurrent craniopharyngiomas. Kobe J Med Sci 49:123–132
25. Baskin DS, Wilson CB (1986) Surgical management of
craniopharyngiomas. A review of 74 cases. J Neurosurg 65:22–27
26. Behari S, Banerji D, Mishra A, Sharma S, Chhabra DK, Jain VK
(2003) Intrinsic third ventricular craniopharyngiomas: report on
six cases and a review of the literature. Surg Neurol 60:245–252
(discussion 252-243)
27. Belen D, Er U, Yigitkanli K, Bolay H (2007) Delayed neuro-
toxic complication of intracavitary bleomycin therapy for cra-
niopharyngioma in a child who had previously undergone
radiosurgery. Case report. J Neurosurg 106:391–393
28. Berlis A, Vesper J, Ostertag C (2006) Stent placement for
intracranial cysts by combined stereotactic/endoscopic surgery.
Neurosurgery 59:ONS474–479; discussion ONS479-480
29. Bhagwati SN, Deopujari CE, Parulekar GD (1990) Lamina
terminalis approach for retrochiasmal craniopharyngiomas.
Childs Nerv Syst 6:425–429
30. Bianco Ade M, Madeira LV, Rosemberg S, Shibata MK (2006)
Cortical seeding of a craniopharyngioma after craniotomy: case
report. Surg Neurol 66:437–440 (discussion 440)
31. Bin-Abbas B, Mawlawi H, Sakati N, Khafaja Y, Chaudhary
MA, Al-Ashwal A (2001) Endocrine sequelae of childhood
craniopharyngioma. J Pediatr Endocrinol Metab 14:869–874
32. Blackburn TP, Doughty D, Plowman PN (1999) Stereotactic
intracavitary therapy of recurrent cystic craniopharyngioma by
instillation of 90yttrium. Br J Neurosurg 13:359–365
33. Boch AL, van Effenterre R, Kujas M (1997) Craniopharyngio-
mas in two consanguineous siblings: case report. Neurosurgery
41:1185–1187
34. Bohn D, Davids MR, Friedman O, Halperin ML (2005) Acute
and fatal hyponatraemia after resection of a craniopharyngioma:
a preventable tragedy. QJM 98:691–703
35. Bremer AM, Nguyen TQ, Balsys R (1984) Therapeutic benefits
of combination chemotherapy with vincristine, BCNU, and
procarbazine on recurrent cystic craniopharyngioma. A case
report. J Neurooncol 2:47–51
36. Broggi G, Franzini A, Cajola L, Pluchino F (1994) Cell kinetic
investigations in craniopharyngioma: preliminary results and
considerations. Pediatr Neurosurg 21 Suppl 1:21–23
37. Buhl R, Nabavi A, Fritsch M, Mehdorn HM (2001) Nasopha-
ryngeal extension of a craniopharyngioma in a 4 year old girl.
Acta Neurochir (Wien) 143:1283–1285
38. Bulow B, Attewell R, Hagmar L, Malmstrom P, Nordstrom CH,
Erfurth EM (1998) Postoperative prognosis in craniopharyngioma
with respect to cardiovascular mortality, survival, and tumor
recurrence. J Clin Endocrinol Metab 83:3897–3904
39. Burkey BB, Speyer MT, Maciunas RJ, Fitzpatrick JM, Galloway
RL Jr, Allen GS (1998) Sublabial, transseptal, transsphenoidal
approach to the pituitary region guided by the ACUSTAR I
system. Otolaryngol Head Neck Surg 118:191–194
40. Cabezudo JM, Vaquero J, Areitio E, Martinez R, de Sola RG,
Bravo G (1981) Craniopharyngiomas: a critical approach to
treatment. J Neurosurg 55:371–375
41. Caceres A (2005) Intracavitary therapeutic options in the man-
agement of cystic craniopharyngioma. Childs Nerv Syst 21:705–
718
42. Caldarelli M, di Rocco C, Papacci F, Colosimo C Jr (1998)
Management of recurrent craniopharyngioma. Acta Neurochir
(Wien) 140:447–454
43. Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C
(2005) Long-term results of the surgical treatment of cranio-
pharyngioma: the experience at the Policlinico Gemelli, Cath-
olic University, Rome. Childs Nerv Syst 21:747–757
44. Calvo FA, Hornedo J, Arellano A, Sachetti A, de la Torre A,
Aragon G, Otero J (1983) Radiation therapy in craniopharyn-
giomas. Int J Radiat Oncol Biol Phys 9:493–496
45. Cavalheiro S, Dastoli PA, Silva NS, Toledo S, Lederman H, da
Silva MC (2005) Use of interferon alpha in intratumoral che-
motherapy for cystic craniopharyngioma. Childs Nerv Syst
21:719–724
46. Cavazzuti V, Fischer EG, Welch K, Belli JA, Winston KR
(1983) Neurological and psychophysiological sequelae follow-
ing different treatments of craniopharyngioma in children.
J Neurosurg 59:409–417
47. Chakrabarti I, Amar AP, Couldwell W, Weiss MH (2005) Long-
term neurological, visual, and endocrine outcomes following
transnasal resection of craniopharyngioma. J Neurosurg
102:650–657
48. Gonc EN, Yordam N, Ozon A, Alikasifoglu A, Kandemir N
(2004) Endocrinological outcome of different treatment options
in children with craniopharyngioma: a retrospective analysis of
66 cases. Pediatr Neurosurg 40:112–119
49. Gsponer J, De Tribolet N, Deruaz JP, Janzer R, Uske A, Mir-
imanoff RO, Reymond MJ, Rey F, Temler E, Gaillard RC,
Gomez F (1999) Diagnosis, treatment, and outcome of pituitary
tumors and other abnormal intrasellar masses. Retrospective
analysis of 353 patients. Medicine (Baltimore) 78:236–269
50. Guidetti B, Fraioli B (1979) Craniopharyngiomas. Results of
surgical treatment. Acta Neurochir Suppl (Wien) 28:349–351
51. Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Sharma BS,
Mehta VS (2006) Recurrence in pediatric craniopharyngiomas:
analysis of clinical and histological features. Childs Nerv Syst
22:50–55
52. Gupta K, Kuhn MJ, Shevlin DW, Wacaser LE (1999) Metastatic
craniopharyngioma. AJNR Am J Neuroradiol 20:1059–1060
53. Gurkaynak M, Ozyar E, Zorlu F, Akyol FH, Atahan IL (1994)
Results of radiotherapy in craniopharyngiomas analysed by the
linear quadratic model. Acta Oncol 33:941–943
54. Habrand JL, Ganry O, Couanet D, Rouxel V, Levy-Piedbois C,
Pierre-Kahn A, Kalifa C (1999) The role of radiation therapy in
the management of craniopharyngioma: a 25-year experience
and review of the literature. Int J Radiat Oncol Biol Phys
44:255–263
55. Hader WJ, Steinbok P, Hukin J, Fryer C (2000) Intratumoral
therapy with bleomycin for cystic craniopharyngiomas in
children. Pediatr Neurosurg 33:211–218
56. Hafez MA, ElMekkawy S, AbdelBadie H, Mohy M, Omar M
(2006) Pediatric craniopharyngioma—rationale for multimodal
470 J Neurooncol (2011) 101:463–476
123
management: the Egyptian experience. J Pediatr Endocrinol
Metab 19 Suppl 1:371–380
57. Hamamoto Y, Niino K, Adachi M, Hosoya T (2002) MR and CT
findings of craniopharyngioma during and after radiation ther-
apy. Neuroradiology 44:118–122
58. Hamlat A, Morandi X, Riffaud L, Carsin-Nicol B, Haegelen C,
Helal H, Brassier G (2008) Transtemporal-transchoroidal
approach and its transamygdala extension to the posterior chi-
asmatic cistern and diencephalo-mesencephalic lesions. Acta
Neurochir (Wien) 150:317–327 (discussion 327-318)
59. Hargrave DR (2006) Does chemotherapy have a role in the
management of craniopharyngioma? J Pediatr Endocrinol Metab
19 Suppl 1:407–412
60. Hasegawa T, Kondziolka D, Hadjipanayis CG, Lunsford LD
(2004) Management of cystic craniopharyngiomas with phos-
phorus-32 intracavitary irradiation. Neurosurgery 54:813–820
(discussion 820-812)
61. Hoff JT, Patterson RH Jr (1972) Craniopharyngiomas in chil-
dren and adults. J Neurosurg 36:299–302
62. Hoffman HJ (1985) Craniopharyngiomas. Can J Neurol Sci
12:348–352
63. Hoffman HJ, De Silva M, Humphreys RP, Drake JM, Smith ML,
Blaser SI (1992) Aggressive surgical management of cranio-
pharyngiomas in children. J Neurosurg 76:47–52
64. Honegger J, Buchfelder M, Fahlbusch R (1999) Surgical treat-
ment of craniopharyngiomas: endocrinological results. J Neu-
rosurg 90:251–257
65. Hoogenhout J, Otten BJ, Kazem I, Stoelinga GB, Walder AH
(1984) Surgery and radiation therapy in the management of
craniopharyngiomas. Int J Radiat Oncol Biol Phys 10:2293–
2297
66. Hukin J, Steinbok P, Lafay-Cousin L, Hendson G, Strother D,
Mercier C, Samson Y, Howes W, Bouffet E (2007) Intracystic
bleomycin therapy for craniopharyngioma in children: the
Canadian experience. Cancer 109:2124–2131
67. Hukin J, Visser J, Sargent M, Goddard K, Fryer C, Steinbok P
(2005) Childhood craniopharyngioma: Vancouver experience.
Childs Nerv Syst 21:758–765
68. Im SH, Wang KC, Kim SK, Chung YN, Kim HS, Lee CH, Cho
BK (2003) Transsphenoidal microsurgery for pediatric cranio-
pharyngioma: special considerations regarding indications and
method. Pediatr Neurosurg 39:97–103
69. Inoue HK, Fujimaki H, Kohga H, Ono N, Hirato M, Ohye C (1997)
Basal interhemispheric supra- and/or infrachiasmal approaches
via superomedial orbitotomy for hypothalamic lesions: preser-
vation of hypothalamo-pituitary functions in combination
treatment with radiosurgery. Childs Nerv Syst 13:250–256
70. Isaac MA, Hahn SS, Kim JA, Bogart JA, Chung CT (2001)
Management of craniopharyngioma. Cancer J 7:516–520
71. Israel ZH, Pomeranz S (1995) Intracranial craniopharyngioma
seeding following radical resection. Pediatr Neurosurg 22:210–
213
72. Ito M, Jamshidi J, Yamanaka K (2001) Does craniopharyngioma
metastasize? Case report and review of the literature. Neuro-
surgery 48:933–935 (discussion 935-936)
73. Ivkov M, Ribaric I, Slavik E, Antunovic V, Samardzic M,
Djordjevic M (1979) Surgical treatment of craniopharyngiomas
in adults. Acta Neurochir Suppl (Wien) 28:352–356
74. Jackson AS, St George EJ, Hayward RJ, Plowman PN (2003)
Stereotactic radiosurgery. XVII: recurrent intrasellar cranio-
pharyngioma. Br J Neurosurg 17:138–143
75. Jakacki RI, Cohen BH, Jamison C, Mathews VP, Arenson E,
Longee DC, Hilden J, Cornelius A, Needle M, Heilman D, Boaz
JC, Luerssen TG (2000) Phase II evaluation of interferon-alpha-
2a for progressive or recurrent craniopharyngiomas. J Neurosurg
92:255–260
76. Jeong IH, Lee JK, Moon KS, Joo SP, Kwak HJ, Kim TS, Kim JH,
Kim SH (2006) Ectopic recurrence of craniopharyngioma: a case
report and review of the literature. J Neurooncol 79:191–195
77. Jialal I, Reddi K, Omar MA, Van Dellen JR, Joubert SM (1986)
Pituitary tumours in African and Indian patients. Trop Geogr
Med 38:175–179
78. Joki T, Oi S, Babapour B, Kaito N, Ohashi K, Ebara M, Kato M,
Abe T (2002) Neuroendoscopic placement of Ommaya reservoir
into a cystic craniopharyngioma. Childs Nerv Syst 18:629–633
79. Jooma R, Kendall BE (1982) Intracranial tumours in the first
year of life. Neuroradiology 23:267–274
80. Julow J, Backlund EO, Lanyi F, Hajda M, Balint K, Nyary I,
Szeifert GT (2007) Long-term results and late complications
after intracavitary yttrium-90 colloid irradiation of recurrent
cystic craniopharyngiomas. Neurosurgery 61:288–295 (discus-
sion 295-286)
81. Julow J, Lanyi F, Hajda M, Simkovics M, Arany I, Toth S,
Pasztor E (1985) The radiotherapy of cystic craniopharyngioma
with intracystic installation of 90Y silicate colloid. Acta Neu-
rochir (Wien) 74:94–99
82. Kabil MS, Shahinian HK (2005) Application of the supraorbital
endoscopic approach to tumors of the anterior cranial base. J
Craniofac Surg 16:1070–1074 (discussion 1075)
83. Kalapurakal JA, Goldman S, Hsieh YC, Tomita T, Marymont
MH (2000) Clinical outcome in children with recurrent cranio-
pharyngioma after primary surgery. Cancer J 6:388–393
84. Kalapurakal JA, Goldman S, Hsieh YC, Tomita T, Marymont
MH (2003) Clinical outcome in children with craniopharyngi-
oma treated with primary surgery and radiotherapy deferred
until relapse. Med Pediatr Oncol 40:214–218
85. Kang JK, Song JU (1988) Results of the management of cra-
niopharyngioma in children. An endocrinological approach to
the treatment. Childs Nerv Syst 4:135–138
86. Karavitaki N, Brufani C, Warner JT, Adams CB, Richards P,
Ansorge O, Shine B, Turner HE, Wass JA (2005) Craniophar-
yngiomas in children and adults: systematic analysis of 121 cases
with long-term follow-up. Clin Endocrinol (Oxf) 62:397–409
87. Katz EL (1975) Late results of radical excision of craniophar-
yngiomas in children. J Neurosurg 42:86–93
88. Kawaguchi T, Fujimura M, Shirane R, Shoji T, Watanabe M,
Tominaga T (2005) Ectopic recurrence of craniopharyngioma. J
Clin Neurosci 12:307–309
89. Keohane C, Hally M, Ryder DQ, Buckley TF (1994) Late
recurrence of craniopharyngioma in the cerebellopontine angle
in a fertile woman. J Neurol Neurosurg Psychiatry 57:873–874
90. Khafaga Y, Jenkin D, Kanaan I, Hassounah M, Al Shabanah M,
Gray A (1998) Craniopharyngioma in children. Int J Radiat
Oncol Biol Phys 42:601–606
91. Kim MS, Lee SI, Sim SH (1999) Brain tumors with cysts treated
with Gamma Knife radiosurgery: is microsurgery indicated?
Stereotact Funct Neurosurg 72 Suppl 1:38–44
92. Kim SD, Park JY, Park J, Lee JB, Kim SH, Lim DJ (2007)
Radiological findings following postsurgical intratumoral bleo-
mycin injection for cystic craniopharyngioma. Clin Neurol
Neurosurg 109:236–241
93. Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK (2001)
Radical excision of pediatric craniopharyngioma: recurrence
pattern and prognostic factors. Childs Nerv Syst 17:531–536
(discussion 537)
94. Chen C, Okera S, Davies PE, Selva D, Crompton JL (2003)
Craniopharyngioma: a review of long-term visual outcome. Clin
Experiment Ophthalmol 31:220–228
95. Chiou SM, Lunsford LD, Niranjan A, Kondziolka D, Flickinger
JC (2001) Stereotactic radiosurgery of residual or recurrent
craniopharyngioma, after surgery, with or without radiation
therapy. Neuro Oncol 3:159–166
J Neurooncol (2011) 101:463–476 471
123
96. Chung WY, Pan DH, Shiau CY, Guo WY, Wang LW (2000)
Gamma knife radiosurgery for craniopharyngiomas. J Neurosurg
93 Suppl 3:47–56
97. Chung WY, Pan HC, Guo WY, Shiau CY, Wang LW, Wu HM,
Lee LS (1998) Protection of visual pathway in gamma knife
radiosurgery for craniopharyngiomas. Stereotact Funct Neuro-
surg 70 Suppl 1:139–151
98. Cinalli G, Spennato P, Cianciulli E, Fiorillo A, Di Maio S,
Maggi G (2006) The role of transventricular neuroendoscopy in
the management of craniopharyngiomas: three patient reports
and review of the literature. J Pediatr Endocrinol Metab 19
Suppl 1:341–354
99. Clayton PE, Price DA, Shalet SM, Gattemaneni HR (1988)
Craniopharyngioma recurrence and growth hormone therapy.
Lancet 1:642
100. Colangelo M, Ambrosio A, Ambrosio C (1990) Neurological
and behavioral sequelae following different approaches to cra-
niopharyngioma. Long-term follow-up review and therapeutic
guidelines. Childs Nerv Syst 6:379–382
101. Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-
Ertner D (2007) Achievement of long-term local control in
patients with craniopharyngiomas using high precision stereo-
tactic radiotherapy. Cancer 109:2308–2314
102. Connolly ES Jr, Winfree CJ, Carmel PW (1997) Giant posterior
fossa cystic craniopharyngiomas presenting with hearing loss.
Report of three cases and review of the literature. Surg Neurol
47:291–299
103. Couldwell WT, Weiss MH, Rabb C, Liu JK, Apfelbaum RI,
Fukushima T (2004) Variations on the standard transsphenoidal
approach to the sellar region, with emphasis on the extended
approaches and parasellar approaches: surgical experience in
105 cases. Neurosurgery 55:539–547 (discussion 547-550)
104. Crotty TB, Scheithauer BW, Young WF Jr, Davis DH, Shaw
EG, Miller GM, Burger PC (1995) Papillary craniopharyngi-
oma: a clinicopathological study of 48 cases. J Neurosurg
83:206–214
105. Danoff BF, Cowchock FS, Kramer S (1983) Childhood crani-
opharyngioma: survival, local control, endocrine and neurologic
function following radiotherapy. Int J Radiat Oncol Biol Phys
9:171–175
106. Dashora U, Mathias D, James A, Zammit-Maempel I, Perros P
(2002) Management of recurrent pituitary cysts with pituitary-
nasal drain. Pituitary 5:225–233
107. Davies MJ, King TT, Metcalfe KA, Monson JP (1997) Intra-
ventricular craniopharyngioma: a long-term follow-up of six
cases. Br J Neurosurg 11:533–541
108. Day JD, Giannotta SL, Fukushima T (1994) Extradural temp-
oropolar approach to lesions of the upper basilar artery and
infrachiasmatic region. J Neurosurg 81:230–235
109. Delitala A, Brunori A, Chiappetta F (2004) Purely neuroendo-
scopic transventricular management of cystic craniopharyngio-
mas. Childs Nerv Syst 20:858–862
110. Demaerel P, Moseley IF, Scaravilli F (1993) Recurrent cranio-
pharyngioma invading the orbit, cavernous sinus and skull base:
a case report. Neuroradiology 35:261–263
111. DeVile CJ, Grant DB, Hayward RD, Stanhope R (1996) Growth
and endocrine sequelae of craniopharyngioma. Arch Dis Child
75:108–114
112. Dhellemmes P, Vinchon M (2006) Radical resection for cra-
niopharyngiomas in children: surgical technique and clinical
results. J Pediatr Endocrinol Metab 19 Suppl 1:329–335
113. Di Rocco C, Caldarelli M, Tamburrini G, Massimi L (2006)
Surgical management of craniopharyngiomas—experience with a
pediatric series. J Pediatr Endocrinol Metab 19 Suppl 1:355–366
114. Djordjevic M, Djordjevic Z, Janicijevic M, Nestorovic B,
Stefanovic B, Ivkov M (1979) Surgical treatment of
craniopharyngiomas in children. Acta Neurochir Suppl (Wien)
28:344–347
115. Economos D (1979) Systemic shunting of residual intraparen-
chymatous cystic craniopharyngioma. Acta Neurochir Suppl
(Wien) 28:363–366
116. el Gammal T, Brooks BS, Hoffman WH (1989) MR imaging of
the ectopic bright signal of posterior pituitary regeneration.
AJNR Am J Neuroradiol 10:323–328
117. Eldevik OP, Blaivas M, Gabrielsen TO, Hald JK, Chandler WF
(1996) Craniopharyngioma: radiologic and histologic findings
and recurrence. AJNR Am J Neuroradiol 17:1427–1439
118. Elwatidy SM, Jamjoom ZA, Jamjoom AB, Yakoub AO (2002)
Craniopharyngioma. Analysis of factors that affect the outcome.
Saudi Med J 23:34–38
119. Ersahin Y, Yurtseven T, Ozgiray E, Mutluer S (2005) Cranio-
pharyngiomas in children: Turkey experience. Childs Nerv Syst
21:766–772
120. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M
(1999) Surgical treatment of craniopharyngiomas: experience
with 168 patients. J Neurosurg 90:237–250
121. Fischer EG, Welch K, Shillito J Jr, Winston KR, Tarbell NJ
(1990) Craniopharyngiomas in children. Long-term effects of
conservative surgical procedures combined with radiation ther-
apy. J Neurosurg 73:534–540
122. Fisher PG, Jenab J, Gopldthwaite PT, Tihan T, Wharam MD,
Foer DR, Burger PC (1998) Outcomes and failure patterns
in childhood craniopharyngiomas. Childs Nerv Syst 14:
558–563
123. Fitzek MM, Linggood RM, Adams J, Munzenrider JE (2006)
Combined proton and photon irradiation for craniopharyngioma:
long-term results of the early cohort of patients treated at
Harvard Cyclotron Laboratory and Massachusetts General
Hospital. Int J Radiat Oncol Biol Phys 64:1348–1354
124. Flickinger JC, Deutsch M, Lunsford LD (1989) Repeat mega-
voltage irradiation of pituitary and suprasellar tumors. Int J
Radiat Oncol Biol Phys 17:171–175
125. Flickinger JC, Lunsford LD, Singer J, Cano ER, Deutsch M
(1990) Megavoltage external beam irradiation of craniophar-
yngiomas: analysis of tumor control and morbidity. Int J Radiat
Oncol Biol Phys 19:117–122
126. Fraioli MF, Santoni R, Fraioli C, Contratti F (2006) ‘‘Conser-
vative’’ surgical approach and early postoperative radiotherapy
in a patient with a huge cystic craniopharyngioma. Childs Nerv
Syst 22:151–155 (discussion 158-163)
127. Frank G, Pasquini E, Doglietto F, Mazzatenta D, Sciarretta V,
Farneti G, Calbucci F (2006) The endoscopic extended trans-
sphenoidal approach for craniopharyngiomas. Neurosurgery
59:ONS75–83 (discussion ONS75-83)
128. Freeman CR, Souhami L, Caron JL, Villemure JG, Olivier A,
Montes J, Farmer JP, Podgorsak EB (1994) Stereotactic external
beam irradiation in previously untreated brain tumors in children
and adolescents. Med Pediatr Oncol 22:173–180
129. Frisen L, Sjostrand J, Norrsell K, Lindgren S (1976) Cyclic
compression of the intracranial optic nerve: patterns of visual
failure and recovery. J Neurol Neurosurg Psychiatry 39:1109–
1113
130. Garcia-Uria J (1978) Surgical experience with craniopharyngi-
oma in adults. Surg Neurol 9:11–14
131. Ghatak NR, White BE (1969) Delayed radiation necrosis of the
hypothalamus. Report of a case simulating recurrent cranio-
pharyngioma. Arch Neurol 21:425–430
132. Gil Z, Constantini S, Spektor S, Abergel A, Khafif A, Beni-
Adani L, Leonor TL, DeRowe A, Fliss DM (2005) Skull base
approaches in the pediatric population. Head Neck 27:682–689
133. Giller CA, Berger BD, Pistenmaa DA, Sklar F, Weprin B,
Shapiro K, Winick N, Mulne AF, Delp JL, Gilio JP, Gall KP,
472 J Neurooncol (2011) 101:463–476
123
Dicke KA, Swift D, Sacco D, Harris-Henderson K, Bowers D
(2005) Robotically guided radiosurgery for children. Pediatr
Blood Cancer 45:304–310
134. Gomez-Daspet J, Elko L, Grebenev D, Vesely DL (2002) Sur-
vival with serum sodium level of 180 mEq/L: permanent dis-
orientation to place and time. Am J Med Sci 324:321–325
135. Kobayashi T, Kida Y, Mori Y, Hasegawa T (2005) Long-term
results of gamma knife surgery for the treatment of craniopha-
ryngioma in 98 consecutive cases. J Neurosurg 103:482–488
136. Kobayashi T, Tanaka T, Kida Y (1994) Stereotactic gamma
radiosurgery of craniopharyngiomas. Pediatr Neurosurg 21
Suppl 1:69–74
137. Kodama T, Matsukado Y, Uemura S (1981) Intracapsular irra-
diation therapy of craniopharyngiomas with radioactive gold:
indication and follow-up results. Neurol Med Chir (Tokyo)
21:49–58
138. Kondziolka D, Nathoo N, Flickinger JC, Niranjan A, Maitz AH,
Lunsford LD (2003) Long-term results after radiosurgery for
benign intracranial tumors. Neurosurgery 53:815–821 (discus-
sion 821-812)
139. Konig A, Ludecke DK, Herrmann HD (1986) Transnasal sur-
gery in the treatment of craniopharyngiomas. Acta Neurochir
(Wien) 83:1–7
140. Konovalov AN, Gorelyshev SK (1992) Surgical treatment of
anterior third ventricle tumours. Acta Neurochir (Wien) 118:33–39
141. Kramer S, Southard M, Mansfield CM (1968) Radiotherapy in
the management of craniopharyngiomas: further experiences
and late results. Am J Roentgenol Radium Ther Nucl Med
103:44–52
142. Kranzinger M, Jones N, Rittinger O, Pilz P, Piotrowski WP,
Manzl M, Galvan G, Kogelnik HD (2001) Malignant glioma as a
secondary malignant neoplasm after radiation therapy for cra-
niopharyngioma: report of a case and review of reported cases.
Onkologie 24:66–72
143. Kristopaitis T, Thomas C, Petruzzelli GJ, Lee JM (2000) Malig-
nant craniopharyngioma. Arch Pathol Lab Med 124:1356–1360
144. Kulkarni V, Daniel RT, Pranatartiharan R (2000) Spontaneous
intraventricular rupture of craniopharyngioma cyst. Surg Neurol
54:249–253 (discussion 253)
145. Kuwabara S, Seo H, Ishikawa S (1987) Huge, dense, cystic
craniopharyngioma with unusual extensions—case report.
Neurol Med Chir (Tokyo) 27:37–41
146. Lange M, Kirsch CM, Steude U, Oeckler R (1995) Intracavitary
treatment of intrasellar cystic craniopharyngeomas with 90-
Yttrium by trans-sphenoidal approach—a technical note. Acta
Neurochir (Wien) 135:206–209
147. Lapras C, Patet JD, Mottolese C, Gharbi S, Lapras C Jr (1987)
Craniopharyngiomas in childhood: analysis of 42 cases. Prog
Exp Tumor Res 30:350–358
148. Larijani B, Bastanhagh MH, Pajouhi M, Kargar Shadab F, Va-
sigh A, Aghakhani S (2004) Presentation and outcome of 93
cases of craniopharyngioma. Eur J Cancer Care (Engl) 13:11–15
149. Laws ER Jr (1994) Transsphenoidal removal of craniopharyn-
gioma. Pediatr Neurosurg 21 Suppl 1:57–63
150. Laws ER Jr, Morris AM, Maartens N (2003) Gliadel for pitui-
tary adenomas and craniopharyngiomas. Neurosurgery 53:255–
269 (discussion 259-260)
151. Lena G, Paz Paredes A, Scavarda D, Giusiano B (2005) Cra-
niopharyngioma in children: Marseille experience. Childs Nerv
Syst 21:778–784
152. Lessell S (1975) Unilateral exophthalmos. Occurrence after
treatment for perichiasmatic neoplasms. JAMA 234:305–306
153. Lichter AS, Wara WM, Sheline GE, Townsend JJ, Wilson CB
(1977) The treatment of craniopharyngiomas. Int J Radiat Oncol
Biol Phys 2:675–683
154. Lin KL, Wang HS, Lui TN (2002) Diagnosis and follow-up of
craniopharyngiomas with transcranial Doppler sonography. J
Ultrasound Med 21:801–806
155. Lippens RJ, Rotteveel JJ, Otten BJ, Merx H (1998) Chemo-
therapy with Adriamycin (doxorubicin) and CCNU (lomustine)
in four children with recurrent craniopharyngioma. Eur J Pae-
diatr Neurol 2:263–268
156. Liu JM, Garonzik IM, Eberhart CG, Sampath P, Brem H (2002)
Ectopic recurrence of craniopharyngioma after an interhemi-
spheric transcallosal approach: case report. Neurosurgery
50:639–644 (discussion 644-635)
157. Locatelli D, Levi D, Rampa F, Pezzotta S, Castelnuovo P (2004)
Endoscopic approach for the treatment of relapses in cystic
craniopharyngiomas. Childs Nerv Syst 20:863–867
158. Long DM, Chou SN (1973) Transcallosal removal of cranio-
pharyngiomas within the third ventricle. J Neurosurg 39:
563–567
159. Lonjon M, Dran G, Casagrande F, Vandenbos F, Mas JC, Ric-
helme C (2005) Prenatal diagnosis of a craniopharyngioma: a
new case with radical surgery and review. Childs Nerv Syst
21:177–180
160. Lunsford LD, Pollock BE, Kondziolka DS, Levine G, Flickinger
JC (1994) Stereotactic options in the management of cranio-
pharyngioma. Pediatr Neurosurg 21 Suppl 1:90–97
161. Luu QT, Loredo LN, Archambeau JO, Yonemoto LT, Slater JM,
Slater JD (2006) Fractionated proton radiation treatment for
pediatric craniopharyngioma: preliminary report. Cancer J
12:155–159
162. Lyen KR, Grant DB (1982) Endocrine function, morbidity, and
mortality after surgery for craniopharyngioma. Arch Dis Child
57:837–841
163. Madhavan M, JG P, Abdullah Jafri J, Idris Z (2005) Intraven-
tricular squamous papillary craniopharyngioma: report of a case
with intraoperative imprint cytology. Acta Cytol 49:431–434
164. Maira G, Anile C, Albanese A, Cabezas D, Pardi F, Vignati A
(2004) The role of transsphenoidal surgery in the treatment of
craniopharyngiomas. J Neurosurg 100:445–451
165. Maira G, Anile C, Colosimo C, Cabezas D (2000) Craniophar-
yngiomas of the third ventricle: trans-lamina terminalis
approach. Neurosurgery 47:857–863 (discussion 863-855)
166. Maira G, Anile C, Rossi GF, Colosimo C (1995) Surgical
treatment of craniopharyngiomas: an evaluation of the trans-
sphenoidal and pterional approaches. Neurosurgery 36:715–724
167. Maira G, Di Rocco C, Anile C, Roselli R (1982) Hyperprolac-
tinemia as the first symptom of craniopharyngioma. Childs
Brain 9:205–210
168. Malik JM, Cosgrove GR, VandenBerg SR (1992) Remote
recurrence of craniopharyngioma in the epidural space. Case
report. J Neurosurg 77:804–807
169. Maniatis AK, Simmons JH, Zeitler PS (2005) Hypothalamic
obesity in a patient with craniopharyngioma: dysregulation of
neurohormonal control of energy balance. Curr Opin Pediatr
17:275–279
170. Maniker AH, Krieger AJ (1996) Rapid recurrence of cranio-
pharyngioma during pregnancy with recovery of vision: a case
report. Surg Neurol 45:324–327
171. Mark RJ, Lutge WR, Shimizu KT, Tran LM, Selch MT, Parker
RG (1995) Craniopharyngioma: treatment in the CT and MR
imaging era. Radiology 197:195–198
172. Mason PW, Krawiecki N, Meacham LR (2002) The use of
dextroamphetamine to treat obesity and hyperphagia in children
treated for craniopharyngioma. Arch Pediatr Adolesc Med
156:887–892
173. Matarazzo P, Genitori L, Lala R, Andreo M, Grossetti R, de
Sanctis C (2004) Endocrine function and water metabolism in
J Neurooncol (2011) 101:463–476 473
123
children and adolescents with surgically treated intra/parasellar
tumors. J Pediatr Endocrinol Metab 17:1487–1495
174. Matson DD, Crigler JF Jr (1969) Management of craniopha-
ryngioma in childhood. J Neurosurg 30:377–390
175. Matthew DJ, Levin M (1986) Pulmonary thromboembolism in
children. Intensive Care Med 12:404–406
176. McMurry FG, Hardy RW Jr, Dohn DF, Sadar E, Gardner WJ
(1977) Long term results in the management of craniopharyn-
giomas. Neurosurgery 1:238–241
177. Merchant TE, Kiehna EN, Sanford RA, Mulhern RK, Thompson
SJ, Wilson MW, Lustig RH, Kun LE (2002) Craniopharyngi-
oma: the St. Jude Children’s Research Hospital experience
1984-2001. Int J Radiat Oncol Biol Phys 53:533–542
178. Minamida Y, Mikami T, Hashi K, Houkin K (2005) Surgical
management of the recurrence and regrowth of craniopharyn-
giomas. J Neurosurg 103:224–232
179. Moon SH, Kim IH, Park SW, Kim I, Hong S, Park CI, Wang
KC, Cho BK (2005) Early adjuvant radiotherapy toward
long-term survival and better quality of life for craniophar-
yngiomas—a study in single institute. Childs Nerv Syst 21:
799–807
180. Mori K, Handa H, Murata T, Takeuchi J, Miwa S, Osaka K
(1980) Results of treatment for craniopharyngioma. Childs
Brain 6:303–312
181. Mottolese C, Stan H, Hermier M, Berlier P, Convert J, Frappaz
D, Lapras C (2001) Intracystic chemotherapy with bleomycin in
the treatment of craniopharyngiomas. Childs Nerv Syst 17:724–
730
182. Mottolese C, Szathmari A, Berlier P, Hermier M (2005) Cra-
niopharyngiomas: our experience in Lyon. Childs Nerv Syst
21:790–798
183. Mudgil AV, Repka MX (2000) Childhood optic atrophy. Clin
Experiment Ophthalmol 28:34–37
184. Muller-Scholden J, Lehrnbecher T, Muller HL, Bensch J, Hen-
gen RH, Sorensen N, Stockhausen HB (2000) Radical surgery in
a neonate with craniopharyngioma. Report of a case. Pediatr
Neurosurg 33:265–269
185. Murphy M, Worth RD, Norris JS (2004) ‘Disappearing’ recur-
rent craniopharyngioma. Br J Neurosurg 18:65
186. Nimsky C, Ganslandt O, Hofmann B, Fahlbusch R (2003)
Limited benefit of intraoperative low-field magnetic resonance
imaging in craniopharyngioma surgery. Neurosurgery 53:72–80
(discussion 80-71)
187. Nishioka H, Ito H, Haraoka J, Hashimoto T, Kato Y (2000)
Repeated hemorrhage in ciliated craniopharyngioma—case
report. Neurol Med Chir (Tokyo) 40:324–328
188. Niu DM, Guo WY, Pan HC, Wong TT (2002) Rapid enlarge-
ment of a residual craniopharyngioma during short-term growth
hormone replacement. Childs Nerv Syst 18:164–165
189. Nomura H, Kurimoto M, Nagai S, Hayashi N, Hirashima Y,
Tsukamoto E, Endo S (2002) Multiple intracranial seeding of
craniopharyngioma after repeated surgery—case report. Neurol
Med Chir (Tokyo) 42:268–271
190. Norris JS, Pavaresh M, Afshar F (1998) Primary transsphenoidal
microsurgery in the treatment of craniopharyngiomas. Br J
Neurosurg 12:305–312
191. Novegno F, Di Rocco F, Colosimo C Jr, Lauriola L, Caldarelli
M (2002) Ectopic recurrences of craniopharyngioma. Childs
Nerv Syst 18:468–473
192. Nyffeler T, Regard M (2001) Kleptomania in a patient with a
right frontolimbic lesion. Neuropsychiatry Neuropsychol Behav
Neurol 14:73–76
193. Ohmori K, Collins J, Fukushima T (2007) Craniopharyngiomas
in children. Pediatr Neurosurg 43:265–278
194. Onoyama Y, Ono K, Yabumoto E, Takeuchi J (1977) Radiation
therapy of craniopharyngioma. Radiology 125:799–803
195. Palaoglu S, Akbay A, Mocan G, Onol B, Ozcan OE, Ozgen T,
Bertan V (1994) Ossified adamantinous type craniopharyngio-
mas. A series of 13 patients. Acta Neurochir (Wien) 127:166–169
196. Pan DH, Lee LS, Huang CI, Wong TT (1990) Stereotactic
internal irradiation for cystic craniopharyngiomas: a 6-year
experience. Stereotact Funct Neurosurg 54–55:525–530
197. Park DH, Park JY, Kim JH, Chung YG, Lee HK, Lee KC, Suh
JK (2002) Outcome of postoperative intratumoral bleomycin
injection for cystic craniopharyngioma. J Korean Med Sci
17:254–259
198. Pemberton LS, Dougal M, Magee B, Gattamaneni HR (2005)
Experience of external beam radiotherapy given adjuvantly or at
relapse following surgery for craniopharyngioma. Radiother
Oncol 77:99–104
199. Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz
NR, van Thiel SW, Corssmit EP, Smit JW, Roelfsema F, Romijn
JA (2005) High prevalence of long-term cardiovascular, neu-
rological and psychosocial morbidity after treatment for crani-
opharyngioma. Clin Endocrinol (Oxf) 62:197–204
200. Plowman PN, Wraith C, Royle N, Grossman AB (1999) Ste-
reotactic radiosurgery. IX. Craniopharyngioma: durable com-
plete imaging responses and indications for treatment. Br J
Neurosurg 13:352–358
201. Pollock BE, Lunsford LD, Kondziolka D, Levine G, Flickinger
JC (1995) Phosphorus-32 intracavitary irradiation of cystic
craniopharyngiomas: current technique and long-term results.
Int J Radiat Oncol Biol Phys 33:437–446
202. Pollock BE, Natt N, Schomberg PJ (2002) Stereotactic man-
agement of craniopharyngiomas. Stereotact Funct Neurosurg
79:25–32
203. Pomeranz HD, Aldrich EF (2004) Intrachiasmal craniopharyn-
gioma: treatment with a cisternal catheter drainage and radia-
tion. J Neuroophthalmol 24:27–30
204. Pritz MB (2002) Ruptured true posterior communicating artery
aneurysm and cystic craniopharyngioma. Acta Neurochir
(Wien) 144:937–939 (discussion 939)
205. Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N,
Zerah M, Bezerra M, Renier D, Pierre-Kahn A, Sainte-Rose C
(2007) Pediatric craniopharyngiomas: classification and treat-
ment according to the degree of hypothalamic involvement. J
Neurosurg 106:3–12
206. Ragel BT, Bishop FS, Couldwell WT (2007) Recurrent infra-
sellar clival craniopharyngioma. Acta Neurochir (Wien)
149:729–730 (discussion 730)
207. Ragoowansi AT, Piepgras DG (1991) Postoperative ectopic
craniopharyngioma. Case report. J Neurosurg 74:653–655
208. Rajan B, Ashley S, Gorman C, Jose CC, Horwich A, Bloom HJ,
Marsh H, Brada M (1993) Craniopharyngioma—a long-term
results following limited surgery and radiotherapy. Radiother
Oncol 26:1–10
209. Rajan B, Ashley S, Thomas DG, Marsh H, Britton J, Brada M
(1997) Craniopharyngioma: improving outcome by early rec-
ognition and treatment of acute complications. Int J Radiat
Oncol Biol Phys 37:517–521
210. Ramnarayan R, Sreehari NR, Ninan GK, John KM (2007)
Delayed postoperative extradural hematoma. Pediatr Neurosurg
43:113–114
211. Regine WF, Mohiuddin M, Kramer S (1993) Long-term results
of pediatric and adult craniopharyngiomas treated with com-
bined surgery and radiation. Radiother Oncol 27:13–21
212. Rehman HU, Atkin SL (1999) Sleep disturbances and cardiac
arrhythmia after treatment of a craniopharyngioma. J R Soc Med
92:585–586
213. Richmond IL, Wara WM, Wilson CB (1980) Role of radiation
therapy in the management of craniopharyngiomas in children.
Neurosurgery 6:513–517
474 J Neurooncol (2011) 101:463–476
123
214. Richmond IL, Wilson CB (1980) Parasellar tumors in children.
II. Surgical management, radiation therapy, and follow-up.
Childs Brain 7:85–94
215. Rilliet B, Vernet O, Pica A (2005) The Geneva and Lausanne
(French-speaking Switzerland) experience: in favor of the
transsphenoidal approach when feasible. Childs Nerv Syst
21:725–728
216. Rodriguez FJ, Scheithauer BW, Tsunoda S, Kovacs K, Vidal S,
Piepgras DG (2007) The spectrum of malignancy in cranio-
pharyngioma. Am J Surg Pathol 31:1020–1028
217. Rudnick EF, DiNardo LJ (2006) Image-guided endoscopic en-
donasal resection of a recurrent craniopharyngioma. Am J Ot-
olaryngol 27:266–267
218. Saaf M, Thoren M, Bergstrand CG, Noren G, Rahn T, Tallstedt
L, Backlund EO (1989) Treatment of craniopharyngiomas—the
stereotactic approach in a ten to twenty-three years’ perspective.
II. Psychosocial situation and pituitary function. Acta Neurochir
(Wien) 99:97–103
219. Samuels MH, Henry P, Kleinschmidt-Demasters B, Lillehei K,
Ridgway EC (1991) Pulsatile prolactin secretion in hyperpro-
lactinemia due to presumed pituitary stalk interruption. J Clin
Endocrinol Metab 73:1289–1293
220. Schefter JK, Allen G, Cmelak AJ, Johnson M, Toms S, Duggan
D, Blevins LS (2002) The utility of external beam radiation and
intracystic 32P radiation in the treatment of craniopharyngio-
mas. J Neurooncol 56:69–78
221. Schulz-Ertner D, Frank C, Herfarth KK, Rhein B, Wannenm-
acher M, Debus J (2002) Fractionated stereotactic radiotherapy
for craniopharyngiomas. Int J Radiat Oncol Biol Phys 54:1114–
1120
222. Scott RM, Hetelekidis S, Barnes PD, Goumnerova L, Tarbell NJ
(1994) Surgery, radiation, and combination therapy in the
treatment of childhood craniopharyngioma—a 20-year experi-
ence. Pediatr Neurosurg 21 Suppl 1:75–81
223. Sener RN, Kismali E, Akyar S, Selcuki M, Yalman O (1997)
Large craniopharyngioma extending to the posterior cranial
fossa. Magn Reson Imaging 15:1111–1112
224. Sepehrnia A, Samii M, Tatagiba M (1991) Management of in-
tracavernous tumours: an 11-year experience. Acta Neurochir
Suppl (Wien) 53:122–126
225. Shapiro K, Till K, Grant DN (1979) Craniopharyngiomas in
childhood. A rational approach to treatment. J Neurosurg
50:617–623
226. Shi XE, Wu B, Zhou ZQ, Fan T, Zhang YL (2006) Microsur-
gical treatment of craniopharyngiomas: report of 284 patients.
Chin Med J (Engl) 119:1653–1663
227. Shinohara O, Shinagawa T, Kubota C, Oi S (1997) Spontaneous
reduction of a recurrent craniopharyngioma in an 8-year-old
female patient: case report. Neurosurgery 41:1188–1190
228. Shirane R, Ching-Chan S, Kusaka Y, Jokura H, Yoshimoto T
(2002) Surgical outcomes in 31 patients with craniopharyngiomas
extending outside the suprasellar cistern: an evaluation of the
frontobasal interhemispheric approach. J Neurosurg 96:704–712
229. Shirane R, Hayashi T, Tominaga T (2005) Fronto-basal inter-
hemispheric approach for craniopharyngiomas extending out-
side the suprasellar cistern. Childs Nerv Syst 21:669–678
230. Shuman AG, Heth JA, Marentette LJ, Blaivas M, Muraszko KM
(2007) Extracranial nasopharyngeal craniopharyngioma: case
report. Neurosurgery 60:E780–E781 (discussion E781)
231. Siomin V, Spektor S, Beni-Adani L, Constantini S (2001)
Application of the orbito-cranial approach in pediatric neuro-
surgery. Childs Nerv Syst 17:612–617
232. Smith AR, Elsheikh TM, Silverman JF (1999) Intraoperative
cytologic diagnosis of suprasellar and sellar cystic lesions. Di-
agn Cytopathol 20:137–147
233. Smith D, Finucane F, Phillips J, Baylis PH, Finucane J, Tormey
W, Thompson CJ (2004) Abnormal regulation of thirst and
vasopressin secretion following surgery for craniopharyngioma.
Clin Endocrinol (Oxf) 61:273–279
234. Snow A, Gozal E, Malhotra A, Tiosano D, Perlman R, Vega C,
Shahar E, Gozal D, Hochberg Z, Pillar G (2002) Severe
hypersomnolence after pituitary/hypothalamic surgery in ado-
lescents: clinical characteristics and potential mechanisms.
Pediatrics 110:e74
235. Sorva R, Heiskanen O (1986) Craniopharyngioma in Finland.
A study of 123 cases. Acta Neurochir (Wien) 81:85–89
236. Sorva R, Heiskanen O, Perheentupa J (1987) Craniopharyngi-
oma in adults. Ann Clin Res 19:339–343
237. Sorva R, Jaaskinen J, Heiskanen O, Perheentupa J (1988)
Postoperative computed tomographic control of 38 patients with
craniopharyngioma. Surg Neurol 29:115–119
238. Sosa IJ, Krieger MD, McComb JG (2005) Craniopharyngiomas
of childhood: the CHLA experience. Childs Nerv Syst 21:785–
789
239. Srinivasan J, Dailey AT, Berger MS (1999) The bifrontal
olfactory nerve-sparing approach to lesions of the suprasellar
region in children. Pediatr Neurosurg 30:245–252
240. Stahnke N, Grubel G, Lagenstein I, Willig RP (1984) Long-term
follow-up of children with craniopharyngioma. Eur J Pediatr
142:179–185
241. Stripp DC, Maity A, Janss AJ, Belasco JB, Tochner ZA,
Goldwein JW, Moshang T, Rorke LB, Phillips PC, Sutton LN,
Shu HK (2004) Surgery with or without radiation therapy in the
management of craniopharyngiomas in children and young
adults. Int J Radiat Oncol Biol Phys 58:714–720
242. Sung DI (1982) Suprasellar tumors in children: a review of
clinical manifestations and managements. Cancer 50:1420–1425
243. Sutton LN, Gusnard D, Bruce DA, Fried A, Packer RJ, Zim-
merman RA (1991) Fusiform dilatations of the carotid artery
following radical surgery of childhood craniopharyngiomas. J
Neurosurg 74:695–700
244. Svien HJ (1965) Surgical experiences with craniopharyngiomas.
J Neurosurg 23:148–155
245. Sweet WH (1976) Radical surgical treatment of craniopharyn-
gioma. Clin Neurosurg 23:52–79
246. Symon L (1983) Microsurgery of the hypothalamus with special
reference to craniopharyngioma. Neurosurg Rev 6:43–49
247. Symon L (1994) An approach to radical excision of cranio-
pharyngioma by the temporal route. Pediatr Neurosurg 21 Suppl
1:64–68
248. Symon L, Pell MF, Habib AH (1991) Radical excision of cra-
niopharyngioma by the temporal route: a review of 50 patients.
Br J Neurosurg 5:539–549
249. Symon L, Sprich W (1985) Radical excision of craniopharyn-
gioma. Results in 20 patients. J Neurosurg 62:174–181
250. Taguchi Y, Tanaka K, Miyakita Y, Sekino H, Fujimoto M
(2000) Recurrent craniopharyngioma with nasopharyngeal
extension. Pediatr Neurosurg 32:140–144
251. Takahashi H, Yamaguchi F, Teramoto A (2005) Long-term
outcome and reconsideration of intracystic chemotherapy with
bleomycin for craniopharyngioma in children. Childs Nerv Syst
21:701–704
252. Tavangar SM, Larijani B, Mahta A, Hosseini SM, Mehrazine M,
Bandarian F (2004) Craniopharyngioma: a clinicopathological
study of 141 cases. Endocr Pathol 15:339–344
253. Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-
Bojorquez D, Morales-Espinosa D, Sotelo J, Arrieta O (2006)
Clinico-pathological and immunohistochemical characteristics
associated to recurrence/regrowth of craniopharyngiomas. Clin
Neurol Neurosurg 108:661–669
J Neurooncol (2011) 101:463–476 475
123
254. Thomas RF, Monacci WT, Mair EA (2002) Endoscopic image-
guided transethmoid pituitary surgery. Otolaryngol Head Neck
Surg 127:409–416
255. Thompson D, Phipps K, Hayward R (2005) Craniopharyngioma
in childhood: our evidence-based approach to management.
Childs Nerv Syst 21:660–668
256. Thompson IL, Griffin TW, Parker RG, Blasko JC (1978) Cra-
niopharyngioma: the role of radiation therapy. Int J Radiat
Oncol Biol Phys 4:1059–1063
257. Thomsett MJ, Conte FA, Kaplan SL, Grumbach MM (1980)
Endocrine and neurologic outcome in childhood craniopharyn-
gioma: Review of effect of treatment in 42 patients. J Pediatr
97:728–735
258. Tomita T, Bowman RM (2005) Craniopharyngiomas in chil-
dren: surgical experience at Children’s Memorial Hospital.
Childs Nerv Syst 21:729–746
259. Tomita T, McLone DG (1993) Radical resections of childhood
craniopharyngiomas. Pediatr Neurosurg 19:6–14
260. Trejos H, Caceres A, Segura JL (2005) Monstrous craniopha-
ryngioma. Case presentations and term proposal. Childs Nerv
Syst 21:1049–1053 (discussion 1054-1045)
261. Ulfarsson E, Lindquist C, Roberts M, Rahn T, Lindquist M,
Thoren M, Lippitz B (2002) Gamma knife radiosurgery for
craniopharyngiomas: long-term results in the first Swedish
patients. J Neurosurg 97:613–622
262. Usanov EI, Hatomkin DM, Nikulina TA, Gorban NA (1999)
Craniopharyngioma of the pineal region. Childs Nerv Syst 15:4–7
263. Van den Berge JH, Blaauw G, Breeman WA, Rahmy A,
Wijngaarde R (1992) Intracavitary brachytherapy of cystic
craniopharyngiomas. J Neurosurg 77:545–550
264. Van Effenterre R, Boch AL (2002) Craniopharyngioma in adults
and children: a study of 122 surgical cases. J Neurosurg 97:3–11
265. Varlotto JM, Flickinger JC, Kondziolka D, Lunsford LD, Deu-
tsch M (2002) External beam irradiation of craniopharyngiomas:
long-term analysis of tumor control and morbidity. Int J Radiat
Oncol Biol Phys 54:492–499
266. Villani RM, Tomei G, Bello L, Sganzerla E, Ambrosi B, Re T,
Giovanelli Barilari M (1997) Long-term results of treatment for
craniopharyngioma in children. Childs Nerv Syst 13:397–405
267. Voges J, Sturm V, Lehrke R, Treuer H, Gauss C, Berthold F
(1997) Cystic craniopharyngioma: long-term results after intra-
cavitary irradiation with stereotactically applied colloidal
beta-emitting radioactive sources. Neurosurgery 40:263–269
(discussion 269-270)
268. Vrionis FD, Saatman D, Sorenson J, Brem S (2002) Microscopic
paraseptal sphenoidotomy approach for pituitary tumors. Cancer
Control 9:223–231
269. Vyramuthu N, Benton TF (1983) The management of cranio-
pharyngioma. Clin Radiol 34:629–632
270. Wara WM, Sneed PK, Larson DA (1994) The role of radiation
therapy in the treatment of craniopharyngioma. Pediatr Neuro-
surg 21 Suppl 1:98–100
271. Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen
H, Zagzag D, Shiminski-Maher T, Flamm ES, Epstein FJ, Miller
DC (1994) Craniopharyngiomas: a clinicopathological analysis
of factors predictive of recurrence and functional outcome.
Neurosurgery 35:1001–1010 (discussion 1010-1001)
272. Weiss M, Sutton L, Marcial V, Fowble B, Packer R, Zimmer-
man R, Schut L, Bruce D, D’Angio G (1989) The role of
radiation therapy in the management of childhood craniopha-
ryngioma. Int J Radiat Oncol Biol Phys 17:1313–1321
273. Wen BC, Hussey DH, Staples J, Hitchon PW, Jani SK, Vigliotti
AP, Doornbos JF (1989) A comparison of the roles of surgery
and radiation therapy in the management of craniopharyngio-
mas. Int J Radiat Oncol Biol Phys 16:17–24
274. Xu JG, You C, Cai BW, Jiang S, Sun H, Guo FY, Yang YB, Wu
B (2005) Microsurgical resection of craniopharyngioma of the
third ventricle via an improved transventricular approach. Chin
Med J (Engl) 118:806–811
275. Yamada Y, Haraoka J, Akimoto J (2006) Ectopic recurrence of
craniopharyngioma. Neurol Med Chir (Tokyo) 46:598–600
276. Yu X, Liu Z, Li S (2000) Combined treatment with stereotactic
intracavitary irradiation and gamma knife surgery for cranio-
pharyngiomas. Stereotact Funct Neurosurg 75:117–122
277. Zona G, Spaziante R (2006) Management of cystic cranio-
pharyngiomas in childhood by a transsphenoidal approach.
J Pediatr Endocrinol Metab 19 Suppl 1:381–388
278. Zuccaro G (2005) Radical resection of craniopharyngioma.
Childs Nerv Syst 21:679–690
279. Zuccaro G, Jaimovich R, Mantese B, Monges J (1996) Com-
plications in paediatric craniopharyngioma treatment. Childs
Nerv Syst 12:385–390 (discussion 390-381)
280. Hosmer DW, Lemeshow S (2000) Applied logistic regression.
Wiley, New York
281. Hosmer DW, Hjort NL (2002) Goodness-of-fit processes for
logistic regression: simulation results. Stat Med 21:2723–2738
282. Yang I, Sughrue ME, Rutkowski MJ, Kaur R, Ivan ME, Aranda
D, Barani IJ, Parsa AT (2010) Craniopharyngioma: a compari-
son of tumor control with various treatment strategies. Neuro-
surg Focus 28: E5
476 J Neurooncol (2011) 101:463–476
123
